The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Ligand expression of the EGFR ligands amphiregulin, epiregulin, and amplification of the EGFR gene to predict for treatment efficacy in KRAS wild-type mCRC patients treated with cetuximab plus CAPIRI and CAPOX: Analysis of the randomized AIO CRC-0104 trial.
Sebastian Stintzing
Honoraria - Merck Serono
Other Remuneration - Merck Serono
Andreas Jung
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Other Remuneration - Merck Serono
Christine Kapaun
No relevant relationships to disclose
Jana Reiche
No relevant relationships to disclose
Dominik Paul Modest
Honoraria - Amgen
Other Remuneration - Merck Serono
Clemens Albrecht Giessen
Other Remuneration - Merck Serono
Ursula Vehling-Kaiser
No relevant relationships to disclose
Martina Stauch
No relevant relationships to disclose
Holger Hass
No relevant relationships to disclose
Ludwig Fischer von Weikersthal
No relevant relationships to disclose
Thomas Kirchner
Consultant or Advisory Role - Amgen; AstraZeneca; Merck Serono; Roche
Stock Ownership - AstraZeneca; Novartis
Honoraria - Amgen; AstraZeneca; Merck Serono; Roche
Research Funding - Roche
Volker Heinemann
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Research Funding - Merck Serono
Other Remuneration - Merck Serono